Rheumatic interstitial pneumonitis pulmonary fibrosis, i.e. connective tissue disease-related interstitial lung disease, is usually treated with hormones and other medications to reduce the inflammatory response, control the progression of the disease, and improve the symptoms, and at the same time requires active treatment of the underlying disease.
Connective tissue disease-related interstitial lung disease is generally difficult to reverse, the clinic usually use glucocorticoid anti-infective treatment to reduce lung inflammation. Commonly used drugs include prednisone and methylprednisone.
It is also recommended to use anti-fibrotic drug treatment, such as pirfenidone, nidanib, etc., to hinder the proliferation of fibroblasts, inhibit pulmonary fibrosis, and improve lung function.
For patients who have dyspnea with a little activity, oxygen therapy is usually needed to correct hypoxemia.
Rheumatism is an autoimmune disease, resulting in interstitial pneumonia, generally need to actively treat the underlying disease, commonly used anti-rheumatic drugs to improve the condition, commonly used drugs such as methotrexate, cyclosporine A, etc., to improve the swelling of the joints, reduce the disease progression of reactive proteins, sedimentation rate, rheumatoid factor and other immune indicators.
Patients with connective tissue disease-related interstitial lung disease are advised to seek timely medical attention to avoid aggravation of the disease. The above drugs need to be used under the supervision of a physician.